# Eric Bell

> Eric Bell is a Series A investor at SpringRock Ventures (Seattle) backing Dental and Health Care. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [SpringRock Ventures](https://shizune.co/investors/profile/springrock-ventures)
- Location: Seattle, United States
- Total investments: 6
- Last investment: Apr 2022
- Lead investor: 50%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/eric-bell/
- X (Twitter): https://twitter.com/erbell
- Website: https://x.com/erbell

Eric Bell is a Series A investor at SpringRock Ventures in Seattle focused on Dental and Health Care. Eric is Managing Director of SpringRock Ventures. He has spent his entire career helping life sciences organization’s translate innovation into commercialization. His investment portfolio includes six investments in companies that have gone public or been acquired. Eric’s notable investments include: Illumina (ILMN), Rosetta Inpharmatics (RSTA –acquired by MRK), Vascular Solutions (VASC), HemoSense (HEM acquired by IMA), SignalSoft (SGSF), and Artemis Medical (acquired by JNJ).Before co-founding SpringRock, Eric headed the Small and Medium Enterprise Program for the Invention Development Fund (IDF) at Intellectual Ventures (IV). Among prior work at IV, he led an international team focused on building a portfolio supporting his investment thesis in medical devices, using IV’s “invention capital” to build a new model for medtech financing – a seed medical device aggregator.Prior to IV, Eric had spent most of his career in venture capital. He was an investment professional at Vulcan Capital, Paul Allen’s investment vehicle, and Tredegar Investments. There, he was responsible for early and mid-stage life sciences investments. Eric has also been Director of Business Development with Corixa Corporation, a biotechnology company in Seattle, WA. There he headed the out-licensing effort for Corixa’s preclinical programs and was responsible for initiating and closing the WT-1 cancer vaccine transaction with the biotechnology division of Kirin Breweries based in Tokyo, Japan.Prior to business school, Eric had worked for a start-up medical device company developing a home hemodialysis machine, Aksys, Ltd. (AKSY). While there, he was awarded several patents for his work on dialyzer reuse. Eric has an M.B.A. from the Wharton School at the University of Pennsylvania, an M.S.E. in Biomedical Engineering from the University of Pennsylvania, and a B.S. in Mechanical Engineering from Worcester Polytechnic Institute.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Dental | 2 | 33% |
| Health Care | 2 | 33% |
| Medical | 1 | 17% |
| Software | 1 | 17% |
| Nutrition | 1 | 17% |

9 industries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| SmileMD | SmileMD is an on-site anesthesia service company bringing anesthesia care teams and logistics to optimize the venue for surgeries. It provides anesthesia to pediatric and adult dental practices in their office setting, reducing anxiety and increasing access to care for thousands of patients each year. They utilize the same safety processes andprocedures as hospitals, and our anesthesia care team allows us to provide the highest quality patient care efficiently and safely. | $9M | Series A | Apr 13, 2022 |  |
| OFFOR Health | OFFOR Health is an on-site care delivery platform that utilizes existing capacity (medical offices, dental offices, etc.) to accelerate surgery backlogs, provide accessibility, and improve outcomes for Medicaid patients. Our core product is SmileMD, which provides accessible pediatric dental anesthesia, and we are expanding into other verticalssuch as Mobile Integrated Healthcare (community paramedicine, dental-driven primary care, vaccinations, etc.). | $9M | Series A | Apr 13, 2022 |  |
| SmileMD | SmileMD is an on-site anesthesia service company bringing anesthesia care teams and logistics to optimize the venue for surgeries. It provides anesthesia to pediatric and adult dental practices in their office setting, reducing anxiety and increasing access to care for thousands of patients each year. They utilize the same safety processes andprocedures as hospitals, and our anesthesia care team allows us to provide the highest quality patient care efficiently and safely. | $6M | Series A | Jan 26, 2021 |  |
| OFFOR Health | OFFOR Health is an on-site care delivery platform that utilizes existing capacity (medical offices, dental offices, etc.) to accelerate surgery backlogs, provide accessibility, and improve outcomes for Medicaid patients. Our core product is SmileMD, which provides accessible pediatric dental anesthesia, and we are expanding into other verticalssuch as Mobile Integrated Healthcare (community paramedicine, dental-driven primary care, vaccinations, etc.). | $5M | Series A | Jan 26, 2021 |  |
| OFFOR Health | OFFOR Health is an on-site care delivery platform that utilizes existing capacity (medical offices, dental offices, etc.) to accelerate surgery backlogs, provide accessibility, and improve outcomes for Medicaid patients. Our core product is SmileMD, which provides accessible pediatric dental anesthesia, and we are expanding into other verticalssuch as Mobile Integrated Healthcare (community paramedicine, dental-driven primary care, vaccinations, etc.). | $5M | Series A | Jan 26, 2021 |  |
| Cyrus Biotechnology | Cyrus Biotechnology builds software tools to accelerate basic research in biotech, pharma, and industrial biotechnology. Cyrus Bench delivers an enterprise version of the Rosetta molecular modeling and design toolkit, with the associated array of bio-molecular computation tools. It was founded in 2014 and headquartered in Seattle, Washington. |  | Series A | Jul 27, 2017 |  |

6 of 6 investments shown.

## Co-investors
- [LOUD Capital](https://shizune.co/investors/profile/loud-capital) — VC Fund, 5 deals together
- [AVP](https://shizune.co/investors/profile/axa-strategic-ventures) — VC Fund, 3 deals together
- [Delta Dental](https://shizune.co/investors/profile/delta-dental-of-california) — VC Fund, 2 deals together
- [MBX Capital](https://shizune.co/investors/profile/mbx-capital) — VC Fund, 2 deals together
- [Trinity Ventures](https://shizune.co/investors/profile/trinity-ventures) — VC Fund, 1 deal together
- [W Fund](https://shizune.co/investors/profile/w-fund) — VC Fund, 1 deal together

## About SpringRock Ventures

VC Fund · Seattle, United States

SpringRock Ventures is a venture capital firm that helps entrepreneurs building compelling companies in an evolving sector. The venture capital firm focuses on digital health, devices, services, oral health, SAAS, consumerization/eCommerce of healthcare, IT, wellness, HIPAA and other innovative companies improving general health. They investin early to late-stage, high growth-potential companies with some demonstrated customer acceptance. SpringRock Ventures was founded in 2015 and is based in Seattle, Washington, USA.

3 contacts available at SpringRock Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Eric Bell | Managing Director | https://shizune.co/investors/profile/eric-bell-b133 |
| Kirsten Morbeck | Managing Director | https://shizune.co/investors/profile/kirsten-morbeck |
| Derek Streat | Venture Partner | https://shizune.co/investors/profile/derek-streat |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Eric Bell invest in?

Eric Bell invests primarily in Dental, Health Care and Medical startups, most often at Series A stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Eric Bell last invest?

The most recent investment recorded for Eric Bell closed in Apr 2022. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co